{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:29:56Z","timestamp":1782127796648,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010391","name":"Tokyo Women's Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010391","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00417-026-07117-3","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:51:45Z","timestamp":1770796305000},"page":"1611-1617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Increased intraocular pressure immediately after aflibercept 8\u00a0mg intravitreal injection for neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8192-2725","authenticated-orcid":false,"given":"Nozomu","family":"Hashiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-6372","authenticated-orcid":false,"given":"Ichiro","family":"Maruko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruka","family":"Maruko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuha","family":"Kakehashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"10432","key":"7117_CR1","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Xiaodong S, Berliner AJ et al (2024) Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomized, double-masked, noninferiority, phase 3 trial. Lancet 403(10432):1141\u20131152. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1","journal-title":"Lancet"},{"key":"7117_CR2","first-page":"87","volume":"120","author":"Y Ogura","year":"2016","unstructured":"Ogura Y, Takahashi K, Iida T (2016) Guidelines for intravitreal injection for macular diseases. J Jpn Ophthalmol Soc 120:87\u201390","journal-title":"J Jpn Ophthalmol Soc"},{"issue":"1","key":"7117_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000446878","volume":"236","author":"H El Chehab","year":"2016","unstructured":"El Chehab H, Agard E, Russo A, Boujnah Y, Dot C (2016) Intraocular pressure spikes after aflibercept intravitreal injections. Ophthalmologica 236(1):43\u201347. https:\/\/doi.org\/10.1159\/000446878","journal-title":"Ophthalmologica"},{"key":"7117_CR4","doi-asserted-by":"publisher","unstructured":"Paris A, Volpe G, Perruchoud-Ader K, Casanova A, Menghini M, Grimaldi G (2024) Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study. Br J Ophthalmol 605. https:\/\/doi.org\/10.1136\/bjo-2024-326053","DOI":"10.1136\/bjo-2024-326053"},{"issue":"3","key":"7117_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5301\/ejo.5000159","volume":"23","author":"H El Chehab","year":"2013","unstructured":"El Chehab H, Le Corre A, Agard E, Ract-Madoux G, Coste O, Dot C (2013) Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection. Eur J Ophthalmol 23(3):277\u2013283. https:\/\/doi.org\/10.5301\/ejo.5000159","journal-title":"Eur J Ophthalmol"},{"key":"7117_CR6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2147\/OPTH.S64721","volume":"8","author":"R Lemos-Reis","year":"2014","unstructured":"Lemos-Reis R, Moreira-Gon\u00e7alves N, Melo AB, Carneiro AM, Falc\u00e3o-Reis FM (2014) Immediate effect of intravitreal injection of bevacizumab on intraocular pressure. Clinical ophthalmology (Auckland, N.Z.) 8:1383\u20131388. https:\/\/doi.org\/10.2147\/OPTH.S64721","journal-title":"Clinical ophthalmology (Auckland, N.Z.)"},{"issue":"3","key":"7117_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1755-3768.2010.01904.x","volume":"90","author":"MM Knip","year":"2012","unstructured":"Knip MM, V\u00e4lim\u00e4ki J (2012) Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Acta Ophthalmol 90(3):254\u2013258. https:\/\/doi.org\/10.1111\/j.1755-3768.2010.01904.x","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"7117_CR8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.ajo.2008.07.007","volume":"146","author":"JE Kim","year":"2008","unstructured":"Kim JE, Mantravadi AV, Hur EY, Covert DJ (2008) Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 146(6):930\u20134.e1. https:\/\/doi.org\/10.1016\/j.ajo.2008.07.007","journal-title":"Am J Ophthalmol"},{"key":"7117_CR9","doi-asserted-by":"publisher","first-page":"9019","DOI":"10.12659\/MSM.910923","volume":"24","author":"Y Karakurt","year":"2018","unstructured":"Karakurt Y, Ucak T, Tasl\u0131 G, Agcayaz\u0131 B, \u0130cel E, Y\u0131lmaz H (2018) The effects of intravitreal ranibizumab, aflibercept or dexamethasone implant injections on intraocular pressure changes. Med Sci Monit 24:9019\u20139025. https:\/\/doi.org\/10.12659\/MSM.910923","journal-title":"Med Sci Monit"},{"issue":"7","key":"7117_CR10","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.ophtha.2005.10.061","volume":"113","author":"MS Benz","year":"2006","unstructured":"Benz MS, Albini TA, Holz ER, Lakhanpal RR, Westfall AC, Iyer MN, Carvounis PE (2006) Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 113(7):1174\u20131178. https:\/\/doi.org\/10.1016\/j.ophtha.2005.10.061","journal-title":"Ophthalmology"},{"issue":"12","key":"7117_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/IJG.0000000000001894","volume":"30","author":"AM Levin","year":"2021","unstructured":"Levin AM, Chaya CJ, Kahook MY, Wirostko BM (2021) Intraocular pressure elevation following intravitreal Anti-VEGF injections: short- and long-term considerations. J Glaucoma 30(12):1019\u20131026. https:\/\/doi.org\/10.1097\/IJG.0000000000001894","journal-title":"J Glaucoma"},{"issue":"9","key":"7117_CR12","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00417-019-04362-7","volume":"257","author":"QN Cui","year":"2019","unstructured":"Cui QN, Gray IN, Yu Y, VanderBeek BL (2019) Repeated intravitreal injections of antivascular endothelial growth factors and risk of intraocular pressure medication use. Graefes Arch Clin Exp Ophthalmol 257(9):1931\u20131939. https:\/\/doi.org\/10.1007\/s00417-019-04362-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"7117_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ajo.2010.04.029","volume":"150","author":"MB Horsley","year":"2010","unstructured":"Horsley MB, Mandava N, Maycotte MA, Kahook MY (2010) Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol 150(4):558-561.e1. https:\/\/doi.org\/10.1016\/j.ajo.2010.04.029","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"7117_CR14","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1167\/iovs.15-18404","volume":"57","author":"HJ Shin","year":"2016","unstructured":"Shin HJ, Kim SN, Chung H, Kim TE, Kim HC (2016) Intravitreal Anti-Vascular endothelial growth factor therapy and retinal nerve fiber layer loss in eyes with Age-Related macular degeneration: a meta-analysis. Invest Ophthalmol Vis Sci 57(4):1798\u20131806. https:\/\/doi.org\/10.1167\/iovs.15-18404","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"7117_CR15","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/BF00946937","volume":"235","author":"CE Riva","year":"1997","unstructured":"Riva CE, Hero M, Titze P, Petrig B (1997) Autoregulation of human optic nerve head blood flow in response to acute changes in ocular perfusion pressure. Graefes Arch Clin Exp Ophthalmol 235(10):618\u2013626. https:\/\/doi.org\/10.1007\/BF00946937","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7117_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep31104","volume":"6","author":"K Yagura","year":"2016","unstructured":"Yagura K, Shinoda K, Matsumoto S et al (2016) Electroretinographic evaluations of retinal function before, just after, and after intravitreal injections. Sci Rep 6:31104. https:\/\/doi.org\/10.1038\/srep31104","journal-title":"Sci Rep"},{"issue":"4","key":"7117_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/02713683.2016.1220592","volume":"42","author":"R Hashimoto","year":"2017","unstructured":"Hashimoto R, Sugiyama T, Ubuka M, Maeno T (2017) Autoregulation of optic nerve head blood flow induced by elevated intraocular pressure during vitreous surgery. Curr Eye Res 42(4):625\u2013628. https:\/\/doi.org\/10.1080\/02713683.2016.1220592","journal-title":"Curr Eye Res"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07117-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07117-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07117-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:48:29Z","timestamp":1779428909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07117-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7117"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07117-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the tenets of the Declaration of Helsinki. The institutional review board at Tokyo Women\u2019s Medical University School of Medicine approved the study, which included OCT observations of eyes with macular and retinal disorders and observational studies of age-related macular degeneration and similar disorders.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Dr. Hashiya receives lecturing and travel fees from Senju Pharmaceutical, Chugai Pharmaceutical, Kowa, Novartis Pharma, and the AMO.Dr. Maruko receives lecturing and travel fees from Bayer Pharmaceuticals, Novartis Pharma, Japan Alcon, Santen, Senju Pharmaceutical, Topcon, Chugai Pharmaceutical, Canon, Nidek, and Nikon. He holds a patent.Dr. Ruka Maruko receives lecturing and travel fees from Chugai Pharmaceutical and Kyowa Kirin.Dr. Kakehashi has nothing to disclose.Dr. Kawahara has nothing to disclose.Dr. Nishihara has nothing to disclose.Dr. Iida receives grants from Nidek, Topcon, Santen, Novartis Pharma, Senju Pharmaceutical, Japan Alcon, HOYA, and AMO; consultant fees from Bayer Pharmaceuticals, Novartis Pharma, Chugai Pharmaceutical, Japan Beringer Ingelheim, and Janssen Pharma; and lecturing and travel fees from Bayer Pharmaceuticals, Novartis Pharma, Japan Alcon, Santen, Senju Pharmaceutical, Topcon, Chugai Pharmaceutical, Canon, Nidek, Otsuka Pharmaceutical, Nikon, and Kyowa Kirin. He holds a patent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}